Literature DB >> 2984331

Fenfluramine stimulation of serum cortisol in patients with major affective disorders and healthy controls: further evidence for a central serotonergic action of lithium in man.

H D Mühlbauer, B Müller-Oerlinghausen.   

Abstract

In order to investigate the influence of lithium long-term medication on serotonergic neurotransmission, fenfluramine stimulation (FFS) was used for the assessment of hormonal effects under serotonergic control. The cortisol plasma concentration following FFS was examined between 8 a.m. and 1 p.m. in 11 manic-depressive subjects under lithium prophylaxis and in 8 untreated euthymic patients. In addition, 11 healthy subjects with FFS, and 12 other subjects without FFS were investigated. The basal cortisol concentrations show considerable variation. Those of the lithium patients were in general found lower than those of the control groups. In both, the controls and the manic-depressive patients without lithium medication, no gross deviation from the expected physiological decline of morning cortisol values was found. A subtle effect of FFS in healthy subjects could be observed. In the lithium patients, however, a significant inversion of the cortisol secretion pattern with a steep increase between 10 and 12 a.m. could be demonstrated. It is concluded that FFS and lithium long-term medication exert an agonistic influence onto central serotonergic neurotransmission. Pharmacological challenge with fenfluramine may prove to be a useful tool for the investigation of serotonergic mechanisms in biological psychiatry.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2984331     DOI: 10.1007/bf01253053

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  49 in total

1.  Effect of lithium on central metabolism of 5-hydroxytryptamine.

Authors:  P Poitou; F Guerinot; C Bohuon
Journal:  Psychopharmacologia       Date:  1974

2.  EEG profiles of fenfluramine, amobarbital and dextroamphetamine in normal volunteers.

Authors:  M Fink; D M Shapiro; T M Itil
Journal:  Psychopharmacologia       Date:  1971

3.  Lithium carbonate and plasma cortisol response in the ffective disorders.

Authors:  S R Platman; R R Fieve
Journal:  Arch Gen Psychiatry       Date:  1968-05

4.  Monoamine uptake into synaptosomes from various regions of rat brain following lithium administration and withdrawal.

Authors:  P Ahluwalia; R L Singhal
Journal:  Neuropharmacology       Date:  1981-05       Impact factor: 5.250

5.  Aggression in humans correlates with cerebrospinal fluid amine metabolites.

Authors:  G L Brown; F K Goodwin; J C Ballenger; P F Goyer; L F Major
Journal:  Psychiatry Res       Date:  1979-10       Impact factor: 3.222

6.  Lithium enhancement of central 5-HT transmission induced by 5-HT precursors.

Authors:  C Sangdee; D N Franz
Journal:  Biol Psychiatry       Date:  1980-02       Impact factor: 13.382

7.  Serotonin function and mechanism of action of antidepressant treatment. Effects of amitriptyline and desipramine.

Authors:  D S Charney; G R Heninger; D E Sternberg
Journal:  Arch Gen Psychiatry       Date:  1984-04

8.  The effect of IV L-tryptophan on prolactin, growth hormone, and mood in healthy subjects.

Authors:  D S Charney; G R Heninger; J F Reinhard; D E Sternberg; K M Hafstead
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

9.  Lithium long-term treatment--does it act via serotonin?

Authors:  B Müller-Oerlinghausen
Journal:  Pharmacopsychiatry       Date:  1985-03       Impact factor: 5.788

10.  Lithium: effects on serotonin receptors in rat brain.

Authors:  S Treiser; K J Kellar
Journal:  Eur J Pharmacol       Date:  1980-06-13       Impact factor: 4.432

View more
  12 in total

Review 1.  Lithium and serotonin function: implications for the serotonin hypothesis of depression.

Authors:  L H Price; D S Charney; P L Delgado; G R Heninger
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

2.  Lithium increases 5-HT-mediated prolactin release.

Authors:  S L McCance; P R Cohen; P J Cowen
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

3.  Childhood serotonergic function and early adult outcomes in youth with ADHD: A 15-year follow-up study.

Authors:  Iliyan Ivanov; Janine Flory; Jeffrey H Newcorn; Jeffrey M Halperin
Journal:  Eur Neuropsychopharmacol       Date:  2018-11-19       Impact factor: 4.600

4.  Myo-inositol attenuates the enhancement of the serotonin syndrome by lithium.

Authors:  O Kofman; U Levin
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

5.  Regional brain metabolic correlates of alpha-methylparatyrosine-induced depressive symptoms: implications for the neural circuitry of depression.

Authors:  J Douglas Bremner; Meena Vythilingam; Chin K Ng; Eric Vermetten; Ahsan Nazeer; Dan A Oren; Robert M Berman; Dennis S Charney
Journal:  JAMA       Date:  2003-06-18       Impact factor: 56.272

6.  Mood stabilizer treatment increases serotonin type 1A receptor binding in bipolar depression.

Authors:  Allison C Nugent; Paul J Carlson; Earle E Bain; William Eckelman; Peter Herscovitch; Husseini Manji; Carlos A Zarate; Wayne C Drevets
Journal:  J Psychopharmacol       Date:  2013-08-07       Impact factor: 4.153

7.  Platelet intracellular calcium in patients with recurrent affective disorders.

Authors:  R A Bothwell; D Eccleston; E Marshall
Journal:  Psychopharmacology (Berl)       Date:  1994-03       Impact factor: 4.530

8.  Serotonergic function during lithium augmentation of refractory depression.

Authors:  E McCance-Katz; L H Price; D S Charney; G R Heninger
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

9.  Increased plasma free serotonin but unchanged platelet serotonin in bipolar patients treated chronically with lithium.

Authors:  F Artigas; M J Sarrias; E Martínez; E Gelpí; E Alvarez; C Udina
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

10.  Anticonvulsant drugs in bipolar disorder.

Authors:  H Grunze; S Schlösser; B Amann; J Walden
Journal:  Dialogues Clin Neurosci       Date:  1999-06       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.